2019
Cost-effectiveness of routine and campaign use of typhoid Vi-conjugate vaccine in Gavi-eligible countries: a modelling study
Bilcke J, Antillón M, Pieters Z, Kuylen E, Abboud L, Neuzil KM, Pollard AJ, Paltiel AD, Pitzer VE. Cost-effectiveness of routine and campaign use of typhoid Vi-conjugate vaccine in Gavi-eligible countries: a modelling study. The Lancet Infectious Diseases 2019, 19: 728-739. PMID: 31130329, PMCID: PMC6595249, DOI: 10.1016/s1473-3099(18)30804-1.Peer-Reviewed Original ResearchConceptsGross domestic productWTP valuesCountry's gross domestic productOptimal strategyCountry-specific willingnessAverage net benefitHealth economic evaluationsGAVI-eligible countriesTyphoid ViPay valueDomestic productVaccine priceWTP thresholdEconomic evaluationVaccine-related costsNet benefitMiddle-income countriesGavi supportVaccine AllianceRoutine immunisationHospital admissionCountriesTCV introductionDALYsTransmission dynamic model
2003
Economic Costs of Influenza-Related Work Absenteeism
Akazawa M, Sindelar JL, Paltiel AD. Economic Costs of Influenza-Related Work Absenteeism. Value In Health 2003, 6: 107-115. PMID: 12641861, DOI: 10.1046/j.1524-4733.2003.00209.x.Peer-Reviewed Original ResearchConceptsNet benefitEconomic costsMedical Expenditure Panel Survey Household ComponentMean productivity costsAverage work lossDollar termsUS dollarsEmployment dataProductivity impactEconomic attractivenessNumber of workdaysWorking-age peopleHousehold ComponentProductivity costsWorker productivityWorker absenteeismEmployment factorsSimple frameworkInfluenza-like illnessDecision analysisReduced absenteeismCostBaseline analysisInfluenza vaccinationTerms of absence